Evogliptin

DRUG11 trials

Conditions

AlbuminuriaBone Diseases, MetabolicCAVDCalcific Aortic Valve DiseaseDiabetes Mellitus, Type 2Liver DysfunctionNon-Alcoholic Fatty Liver DiseaseOsteoporosis

Phase 1

Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

CompletedNCT02754219

Dong-A ST Co., Ltd.Liver Dysfunction

Start: 2016-09-22End: 2018-01-19Updated: 2018-02-26

Phase 2

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

CompletedNCT02689362

Eurofarma Laboratorios S.A.Diabetes Mellitus, Type 2

Start: 2017-08-08End: 2018-08-09Updated: 2018-08-14

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

CompletedNCT03667300

Samsung Medical CenterAlbuminuria, Renal Insufficiency, Type2 Diabetes Mellitus

Start: 2017-03-16End: 2019-05-14Updated: 2019-09-23

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

SuspendedNCT05143177

REDNVIA Co., Ltd.Calcific Aortic Valve Disease

Start: 2022-06-27End: 2026-12-30Target: 580Updated: 2026-03-27

Phase 3

Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

CompletedNCT02949193

Dong-A ST Co., Ltd.Type 2 Diabetes Mellitus

Start: 2013-05-31End: 2015-05-31Updated: 2016-10-31

Phase 4

Effect of Evogliptin on Bone Metabolism in Human

NCT02587975

DongGuk UniversityDiabetes Mellitus, Type 2, Osteoporosis

Start: 2016-06-30End: 2017-03-31Target: 20Updated: 2016-07-25

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

CompletedNCT02974504

Dong-A ST Co., Ltd.Type2 Diabetes

Start: 2016-09-30End: 2018-03-31Updated: 2018-07-23

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

CompletedNCT03910361

Dong-A ST Co., Ltd.Non-Alcoholic Fatty Liver Disease, Type2 Diabetes

Start: 2019-04-12End: 2020-07-02Updated: 2021-04-29

Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

NCT04521452

Asan Medical CenterCAVD

Start: 2020-09-30End: 2024-09-30Target: 218Updated: 2020-08-20

A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

NCT04706637

Kyung Hee University Hospital at GangdongBone Diseases, Metabolic, Diabetes Mellitus, Type 2

Start: 2021-02-01End: 2023-01-31Target: 120Updated: 2021-01-13

Unknown Phase

Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

NCT04326166

Dong-A ST Co., Ltd.Diabetes Mellitus, Type 2

Start: 2020-03-25End: 2021-07-31Target: 1971Updated: 2021-02-17

Related Papers

Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study.

2019-12-195 citations

1140-P: Efficacy and Safety of Evogliptin in Patients with Type 2 Diabetes: A Multicenter, Active-Controlled, Randomized Study with Open Label Extension (EVERGREEN Study)

Diabetes2019-06-011 citations